Global non-profit CARB-X awards more than AUD$2.6 million to University of Melbourne’s Doherty Institute to fight antibiotic resistance
Posted: 17 October 2023 University of Melbourne researchers from the Peter Doherty Institute for Infection and Immunity (Doherty Institute) are developing a world-first treatment for antibiotic-resistant community-acquired bacterial pneumonia (CABP). The AUD$2.68M (US$1.75M) award by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator…
Cartherics appoints new Chief Scientific Officer
Posted: 17 October 2023 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately.…
PROOF-OF-CONCEPT CLINICAL TRIAL SUCCESSFULLY COMPLETED WITH LAT8881
Posted: 17 October 2023 Lateral Pharma has successfully completed its LAT8881 Phase 1b clinical trial in patients with chronic lumbar radicular pain (a condition commonly referred to as “sciatica”).1,2 The results from this study have demonstrated clinical “proof-of-concept”…
When cells go boom: study reveals inflammation-causing gene carried by millions
Posted: 12 October 2023 Researchers have found that a genetic change that increases the risk of inflammation, through a process described as ‘explosive’ cell death, is carried by up to 3% of the global population. The WEHI-led study…
Monash University co-leads report into precision medicine in diabetes
Posted: 12 October 2023 A new international consensus report on precision medicine in diabetes prevention and care has been published in Nature Medicine. The report, with Dr Siew Lim, from Monash University’s Eastern Health Clinical School, as the…
Seizure Forecasting App To Empower People With Epilepsy
Posted: 12 October 2023 In 2019 there were approximately 150,000 patients diagnosed with epilepsy resulting in $12.3 billion of direct and indirect costs1,2. It is now estimated that up to 200,000 Australians face the daily prospect of debilitating…
Tails From Southern Africa
Posted: 11 October 2023 Elane Zelcer – My Photographs & Stories from Southern Africa Profits from sales of the book, less printing costs, together with sales from other items, will be donated to the Murdoch Children’s Research Institute (MCRI), Australia’s…
A Bright Future for Life Sciences in Australia
Posted: 10 October 2023 Tax Incentives can free up company finances to focus on business-critical activities. This paper will cover 4 key topics that we at Prime Financial believe are essential reading for key decision-makers for companies in…
New blood test could improve concussion diagnosis: study
Posted: 6 October 2023 A global blood test for concussion could be a step closer after a Monash University-led study discovered specific proteins or biomarkers that can help diagnose concussions relatively quickly and accurately. Once approved, a blood…
Update on Nasodine Trial and Forward Plans
Posted: 6 October 2023 Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) announces that the independent preliminary investigation into the Phase 3 trial results of Nasodine Nasal Spray (“Nasodine”) (refer ASX announcement 13 September 2023) has not revealed any systematic…
US FDA grants Orphan Drug Designation for CRO-67
Posted: 6 October 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) status to Noxopharm’s CRO-67 preclinical drug candidate, for the treatment of pancreatic cancer. The…
Xprecia Prime 4U approved for Patient Self-Testing in Europe
Posted: 6 October 2023 Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received the approval required for the sale of “Xprecia Prime 4U” directly to patients for self-testing in Europe. The approval is in the…
